Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Velaglucerase alfa (VPRIV®) is recommended as an option for use within NHS Wales for long-term enzyme replacement therapy in patients with type 1 Gaucher disease. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised. |
|||
|
|||
Medicine details |
|||
| Medicine name | velaglucerase alfa (VPRIV®) | ||
| Formulation | 400 units powder for solution for infusion | ||
| Reference number | 571 | ||
| Indication | Long-term enzyme replacement therapy in patients with type 1 Gaucher disease |
||
| Company | Shire Pharmaceuticals Ltd | ||
| BNF chapter | Nutrition & blood | ||
| Assessment type | Full | ||
| Status | Recommended | ||
| Advice number | 1214 | ||
| NMG meeting date | 14/05/2014 | ||
| AWMSG meeting date | 11/06/2014 | ||
| Ratification by Welsh Government | 24/07/2014 | ||
| Date of issue | 25/07/2014 | ||
| Date of last review | 29/09/2017 | ||
| Commercial arrangement | WPAS | ||